Promius Pharma
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
200 Somerset Corporate Blvd Fl 7, Bridge...Phone Number
(609) 282-1400Website
www.promiuspharma.comRevenue
$27 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Promius Pharma
Promius Pharma is a wholly-owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology.Explore more
Promius Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Promius Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Promius Pharma is spiking on competitors!
Earning: See what the market has to say on Promius Pharma recently announced quarterly report
Promius Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Promius Pharma
Funding: Get notified immidiatlly once Promius Pharma has new funding data
Click to see if Promius Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Promius Pharma launches new products
Website visits: Recent activity has been detected on your website
Check if Promius Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Promius Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Promius Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Promius Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Promius Pharma.
Promius Pharma Tech Stack
A closer look at the technologies used by Promius Pharma
Most Recent Scoops
Divestiture
Divestitures
Project
A mid-level source has indicated that initiatives related to customer data platform are currently in progress. Vishwavijay Singh currently serves as Director & Head of Commercial Analytics & Insights.
CRM, Business Intelligence, Request for Proposal (RFP), Analytics & Insights, Data Management
Pain Point
A mid-level source has indicated that the organization is experiencing challenges related to keeping data clean. Vishwavijay Singh currently serves as Director & Head of Commercial Analytics & Insights.
Pain Point, Analytics & Insights, Data Management
Project
Advertising, Request for Proposal (RFP), Analytics & Insights, SEO / SEM, Social Media, Search
Promius Pharma News & Media
Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults
MAPLE GROVE, Minn., July 20, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has completed the acquisition of Tosymra™ (sumatriptan) Nasal Spray, 10 mg, and Zembrace® SymTouch® (sumatriptan) Injection 3 mg from Dr. Reddy's Laboratories Limited....Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA™ to Upsher-Smith Laboratories, LLC
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended. Under the agreement Dr. Reddy’s sold its US and select territory rights forDr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA™ (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which are commercialized through itsUpsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)
MAPLE GROVE, Minn., June 13, 2019 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has agreed to acquire US and other territory rights for Tosymra™ (sumatriptan nasal spray) 10 mg and Zembrace® SymTouch® (sumatriptan injection) 3 mg from Dr. Reddy's...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Promius Pharma
Sign Up For FreeTo access detailed company insights
Promius Pharma is a wholly-owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patient... Read More
